BTIG starts Sutro Biopharma at buy; PT $19

BTIG initiated coverage of Sutro Biopharma (NASDAQ:STRO) with a “buy” rating and $19 price target. The stock closed at $8.43 on Oct. 4.

Sutro exploits rapid DNA-to-protein cycle times of cell free biosynthesis to produce better-optimized therapeutics, shaving nine-to-15 months of pre-clinical development times. “This approach has already resulted in $350-million in partnership funding with up to $2.5-billion to come,” writes analyst Thomas Shrader. 

Internally, he said company is focused on developing antibody-drug conjugates (ADCs), cytokine-based therapies, and checkpoint inhibitors. 

The company currently has two independent programs in the clinic: SRTO-001 and STRO-002. 

Mr. Shrader said STRO-001 is an ADC against a novel target that the company is evaluating for multiple myeloma (MM) and non-Hodgkin’s lymphoma. Sutro’s other asset, SRTO-002, is being assessed for ovarian and endometrial cancer. 

Partnered programs include a B-cell maturation antigen-ADCwith Celgene designed for reduced ocular toxicity and a precision cytokine pegylation program with Merck, he added.

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.